The live presentation will take place on April 16, 2020, 3:00-4:00pm ET.
Advanced registration is encouraged. Registrants will receive an event reminder by email one day prior to the webinar.
This webinar will briefly review the science and pharmacology that led to the development of ketamine and esketamine as a treatment for neuropsychiatric disorders. It will specifically focus on major issues to be contemplated when considering recommending treatment with ketamine or esketamine to treat severe and persistent major depressive disorder. We will critically review the existing data from a wide range of clinical trials and attempt to incorporate this data into clinical decision making processes.
FREE - $0
Funding for this initiative was made possible (in part) by Grant No. 1H79SM080818-01 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.
- Explain indications for use of ketamine in the treatment of serious and persistent mood disorders
- Evaluate clinical trials examining the efficacy and safety of ketamine and esketamine
- Describe challenges to implementing ketamine into practice
Nurse/Nurse Practitioner, Physician (non-psychiatrist), Physician Assistant, Psychiatrist, Pharmacist
Estimated Time to Complete
Estimated Duration: 1.0 hour
Program Start Date: April 16, 2020
Program End Date: April 16, 2020
Attendees will have an opportunity to participate in Q&A.
How to Earn Credit
Participants who wish to earn AMA PRA Category 1 Credit™, nursing continuing professional development pharmacology contact hours (NCPD, formerly CNE), or a certificate of participation may do so by attending the live presentation and completing the evaluation. Participants claiming CE credit for psychologists must attend the full presentation to claim credit. After evaluating the program, course participants will be provided with an opportunity to claim hours of participation and print an official CME certificate (physicians), NCPD certificate (nursing), or certificate of participation (non-physicians) showing the event date and hours earned.
Continuing Education Credit
The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The APA designates this live event for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The American Psychiatric Nurses Association is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.
Faculty and Planner Disclosures
- Gerard Sanacora, MD, PhD, Associate Professor and Director of the Yale Depression Research Program, Yale University. Disclosures - Off-label medication use will be discussed; Stock: Biohaven Pharmaceuticals; Consultant: Allergan, Alkermes, AstraZeneca, Avanier, Axsome Therapeutics, Pharmaceuticals, Biohaven Pharmaceuticals, BristolMyers Squibb, Clexio Biosciences, EMA Wellness, Epiodyne, Intra-Cellular Therapies, Janssen, Merck & Co., Naurex, Navitor, NeruoRx, Novartis, Noven Pharmaceuticals, Otsuka, Perception Neuroscience, Praxis Therapeutics, Sage Pharmaceuticals, Servier Pharmaceuticals, Taisho Pharmaceuticals, Teva, Valeant, and Vistagen Therapeutics; Grant/Research: AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Johnson & Johnson, Hoffman La-Roche, Merck, Naurex, and Servier over the last 36 months. Free medication was provided to GS for an NIH-sponsored study by Sanofi-Aventis.Other: Co-inventor on a patent ‘Glutamate agents in the treatment of mental disorders’ (Patent number: 8778979), and a U.S. Provisional Patent Application No. 047162-7177P1 (00754) filed on August 20, 2018 by Yale University Office of Cooperative Research OCR 7451 US01.
- Teri Brister, PhD, LPC, National Alliance on Mental Illness. Reports no financial relationships with commercial interests.
- Tristan Gorrindo, MD, American Psychiatric Association. Reports no financial relationships with commercial interests.
- Donna Rolin, PhD, APRN, University of Texas at Austin. Reports no financial relationships with commercial interests.
Accessibility for Participants with Disabilities
The American Psychiatric Association is committed to ensuring accessibility of its website to people with disabilities. Please contact the American Psychiatric Association at 202-559-3900, if you require assistance seven (7) days prior to the start of a live webinar.
We recommend that prior to the webinar, you check system requirements to ensure your device is compatible and rule out connectivity issuess.
Optimal System Configuration
- Flash Player: Adobe Flash Player 10.3+
- Browser: Firefox (latest version), Internet Explorer 8.0+, Safari 7.0+, Microsoft Edge (latest version) or Google Chrome (latest version)
- Operating System: Windows XP+ or Mac OS X 10.4+
- Internet Connection: 1 Mbps or higher
- Windows PC: 500-MHz Pentium II; Windows XP or higher; 128 MB RAM; Video Card at least 64MB of video memory; Macromedia Flash Player 10.3 or higher; Sound Card at least 16-bit; audio playback with speakers for programs with video content
- Macintosh:Mac OS X 10.4+ or higher with latest updates installed; 1.83MHz Intel Core Duo or faster; RAM: 128MB or more; Video Card: at least 64MB of video memory; Sound Card: at least 16-bit; audio playback with speakers for programs with video content
For assistance: Contact email@example.com for questions about this course | Contact SMIAdviserHelp@psych.org for technical assistance